Human Genome Sciences (HGSI)
$27.38
0.16 (+0.59%)
| CAPS Rating |
|
|---|---|
| Open | $26.99 |
| Previous Close | $27.22 |
| Daily Range | $26.55 - $27.59 |
| 52-Week Range | $0.45 - $29.48 |
| Market Cap | $4.52B |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 5,926,722 |
| Average Daily Volume | 9,233,000 |
HGSI
VS S&P 500 (SPY)
How do you think HGSI will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
HGSI Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
HGSI News and Commentary
- What to Do When the Dow Hits 7,500 Again – The Motley Fool
- UPDATE 1-Human Genome's anthrax drug denied approval – Reuters
- Wall Street's Buy List – The Motley Fool
- Stock Smackdown: Cramer vs. CAPS – The Motley Fool
- CNBC on Human Genome Sciences, Inc. – Ockham-RazorWire
- This Will Change the Way You Invest – The Motley Fool
- CNBC on Human Genome Sciences, Inc. – Ockham-RazorWire
- 10 Stocks Shaking the Market – The Motley Fool
- Finally Convinced? Benlysta Works! – The Motley Fool
- UPDATE 1-Human Genome lupus drug succeeds in late-stage trial – Reuters
- Earnings? Yawn. Trial Data? Moving! – The Motley Fool
- PREVIEW-Human Genome poised for biggest day in its history – Reuters
- UPDATE 1-More study needed on Human Genome anthrax drug – Reuters
- Stock Smackdown: Cramer vs. CAPS – The Motley Fool
- U.S. FDA advisory meetings through Dec. 15 – Reuters
- UPDATE 1-FDA: Human Genome anthrax drug data raises issues – Reuters
- UPDATE 1-Human Genome anthrax drug said to work in animals – Reuters
- U.S. FDA advisory meetings through Dec. 8 – Reuters
- UPDATE 1-Human Genome lupus data cheers investors, shares up – Reuters
- Human Genome reports additional lupus drug data – Reuters
RSS Headlines
Fool UK
